Microtubule stabilization reduces scarring and causes axon regeneration after spinal cord injury

Science

Volumn 331, Issue 6019, 2011, Pages 928-931

  Hellal, Farida ^a   Hurtado, Andres ^b   Ruschel, Jörg ^a   Flynn, Kevin C ^a   Laskowski, Claudia J ^a   Umlauf, Martina ^a   Kapitein, Lukas C ^c,d   Strikis, Dinara ^e   Lemmon, Vance ^e   Bixby, John ^e   Hoogenraad, Casper C ^c,d   Bradke, Frank ^a  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; TRANSFORMING GROWTH FACTOR BETA;

CELL ORGANELLE; FUNCTIONAL MORPHOLOGY; INJURY; NEUROLOGY; POLYSACCHARIDE; RODENT; STABILIZATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERTROPHIC SCAR; MICROTUBULE; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEOGLYCAN SYNTHESIS; RAT; SCAR FORMATION; SENSORY NERVE CELL; SIGNAL TRANSDUCTION; SPINAL CORD INJURY;

ANIMALS; AXONS; CELLS, CULTURED; CHONDROITIN SULFATE PROTEOGLYCANS; CICATRIX; FEMALE; GANGLIA, SPINAL; KINESIN; MICROTUBULES; PACLITAXEL; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; SENSORY RECEPTOR CELLS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SPINAL CORD; SPINAL CORD INJURIES; SPINAL CORD REGENERATION; TRANSFORMING GROWTH FACTOR BETA;

RODENTIA;

EID: 79951851076     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1201148     Document Type: Article

References (31)

1. X. Liu et al., PLoS Med. 2, e354 (2005).
2. S. Westermann, K. Weber, Nat. Rev. Mol. Cell Biol. 4, 938 (2003).
3. A. Ertürk, F. Hellal, J. Enes, F. Bradke, J. Neurosci. 27, 9169 (2007).
4. H. Witte, D. Neukirchen, F. Bradke, J. Cell Biol. 180, 619 (2008).
5. N. Klapka, H. W. Müller, J. Neurotrauma 23, 422 (2006).
6. M. C. Shearer et al., Mol. Cell. Neurosci. 24, 913 (2003).
7. J. Silver, J. H. Miller, Nat. Rev. Neurosci. 5, 146 (2004).
8. E. K. Rowinsky, L. A. Cazenave, R. C. Donehower, J. Natl. Cancer Inst. 82, 1247 (1990).
9. S. Okada et al., Nat. Med. 12, 829 (2006).
10. C. Schachtrup et al., J. Neurosci. 30, 5843 (2010).
11. H. L. Moses, R. J. Coffey Jr., E. B. Leof, R. M. Lyons, J. Keski-Oja, J. Cell. Physiol. Suppl. 133 (S5), 1 (1987).
12. D. Lindholm, E. Castrén, R. Kiefer, F. Zafra, H. Thoenen, J. Cell Biol. 117, 395 (1992).
13. J. Batut, M. Howell, C. S. Hill, Dev. Cell 12, 261 (2007).
14. C. Dong, Z. Li, R. Alvarez Jr., X. H. Feng, P. J. Goldschmidt-Clermont, Mol. Cell 5, 27 (2000).
15. S. Dunn et al., J. Cell Sci. 121, 1085 (2008).
16. L. C. Kapitein et al., Biophys. J. 99, 2143 (2010).
17. L. L. Jones, Y. Yamaguchi, W. B. Stallcup, M. H. Tuszynski, J. Neurosci. 22, 2792 (2002).
18. E. J. Bradbury et al., Nature 416, 636 (2002).
19. A. Hurtado, H. Podinin, M. Oudega, B. Grimpe, Brain 131, 2596 (2008).
20. T. L. Laabs et al., J. Neurosci. 27, 14494 (2007).
21. B. Ylera et al., Curr. Biol. 19, 930 (2009).
22. J. Dill, H. Wang, F. Zhou, S. Li, J. Neurosci. 28, 8914 (2008).
23. D. D. Pearse et al., Nat. Med. 10, 610 (2004).
24. S. W. Scheff, A. G. Rabchevsky, I. Fugaccia, J. A. Main, J. E. Lumpp Jr., J. Neurotrauma 20, 179 (2003).
25. D. L. Behrmann, J. C. Bresnahan, M. S. Beattie, B. R. Shah, J. Neurotrauma 9, 197 (1992).
26. P. Freund et al., Nat. Med. 12, 790 (2006).
27. P. Dergham et al., J. Neurosci. 22, 6570 (2002).
28. G. Yiu, Z. He, Nat. Rev. Neurosci. 7, 617 (2006).
29. S. Neumann, F. Bradke, M. Tessier-Lavigne, A. I. Basbaum, Neuron 34, 885 (2002).
30. J. Qiu et al., Neuron 34, 895 (2002).
31. We thank C. Hill for the SMAD2-PAGFP plasmid; A. Ullrich for the HaCaT cells; Ariad Pharmaceuticals for FKBP/FRB plasmids and Rapalog; G. Morfini for technical advice; K. Dornmair, M. Hübener, R. Klein, D. Neukirchen, M. Stiess, S. Tahirovic, and H. Wekerle for critically reading the manuscript; and V. Ha, T. Irl, D.F. Wendell, and R. Zenke for technical assistance. This work was supported by the Max-Planck-Society, Deutsche Forschungsgemeinschaft, International Foundation for Paraplegia, and Human Frontier Science Program (F.B.); NIH ( J.B.); Netherlands Organization for Scientific Research (NWO)-Veni (L.C.K.); Netherlands Organization for Health Research and Development (ZonMW)-TOP, European Science Foundation Young Investigator Award, and NWO-VICI (C.C.H.); and a Marie Curie Fellowship (K.C.F.). The Max-Planck-Society has filed a patent on the use of Taxol after spinal cord injury.